Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
69
resultados
Última actualización
24/04/2026 [07:06:00]
Resumen de: US20260102421A1
A method of treatment of Sars-COV-2 viral infections including Covid-19 and long Covid and of virus associated cognitive impairment and Lewy-Body Spectrum Dementia disorders in a six-agent treatment regimen of hydroxychloroquine, azithromycin, zinc, quercetin, vitamin C, and vitamin D3. The six-agent treatment is administered to the subject orally for, preferably, 5 days at which time the subject is cured of Covid-19. In an alternant embodiment, the method comprises administering to a subject an eight-agent treatment regimen of hydroxychloroquine, azithromycin, zinc, quercetin, vitamin C, vitamin D3, pregnenolone, and niacinamide. The addition of pregnenolone, and niacinamide to the six-agent treatment enhances the improvement of cognitive performance.
Resumen de: US20260103506A1
The present disclosure is directed to antibodies and antigen binding fragments thereof, having improved binding specificity for coronaviruses, such as SARS-CoV-2, including neutralizing antibodies. Other embodiments contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.
Resumen de: US20260102474A1
The present invention relates to therapeutic proteins and medical uses thereof. The present invention relates to modified ACE2 protein having increased binding affinity for the SARS-COV-2 spike protein compared to wildtype ACE2 protein, wherein said modified ACE2 protein is lacking enzymatic activity and is fused to (i) a modified Fc domain of human immunoglobulin, wherein the Fc domain has either enhanced immunostimulating activity (Fc+) or attenuated immunostimulating activity (Fc−) or (ii) a protein that specifically binds to T cells or further enhances immunostimulating activity. The invention also relates to a polynucleotide encoding the modified ACE2 protein of the present invention, a vector or expression construct comprising the polynucleotide, a host cell comprising the polynucleotide or the vector or expression construct, and a non-human transgenic organism comprising the polynucleotide or the vector or expression construct. Moreover, the present invention relates also to a method for the manufacture of a modified ACE protein according to the present invention and to a medicament comprising the modified ACE2 protein, the polynucleotide or the vector or expression construct of the invention. Furthermore, the invention relates to medical uses of the modified ACE2 protein, the polynucleotide or the vector or expression construct in treating and/or preventing a disease or disorder associated with SARS-COV-2 infection. Finally, the invention provides a kit comprising t
Resumen de: AU2024354738A1
Provided are coronavirus spike protein variants for use as antigens for vaccines for coronavirus infections. The present invention provides coronavirus spike protein variants comprising (a) a receptor binding domain (RBD) formed from the amino acid sequence set forth in SEQ ID NO: 1, (b) an RBD formed from an amino acid sequence in which one to several amino acids have been substituted, deleted, inserted, or added in the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to RBD formed from the amino acid sequence set forth in SEQ ID NO: 1, or (c) an RBD formed from an amino acid sequence having at least 90% sequence identity with the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to RBD formed from the amino acid sequence set forth in SEQ ID NO: 1.
Resumen de: US20260098861A1
A phage for the specific capture of the SARS-CoV-2 virus, said phage being an M13 phage engineered to display on the P8 protein of its coat either FHKGGYEKTWKLGD sequence peptides or EFTSKAR sequence peptides, said peptides having specific affinity for the Spike S1 protein of the SARS-CoV-2 virus.
Resumen de: US20260098868A1
A method of diagnosing long-COVID-19 in a patient, the method comprising: (a) obtaining a test sample from the patient, (b) performing one or more assays configured to detect a level of one or more biomarkers in the test sample, (c) comparing the level of the one or more proteins in the test sample with a healthy control reference value of said one or more proteins, wherein a change in the level of the one or more biomarkers in the test sample relative to the healthy control reference value of said one or more proteins is indicative of long-COVID-19 diagnosis, wherein the one or more proteins are selected from Table 3.
Resumen de: US20260097115A1
0000 Immunogenic compositions comprising one or more peptides, wherein the one or more peptides: are capable of binding to Major Histocompatibility Complex (MHC) class II, and are derived from one or more translation products of SARS-CoV-2. Also provided include methods of treating and preventing diseases using the immunogenic compositions.
Resumen de: US20260097114A1
The disclosures of the invention are directed to the manufacture of effective, affordable vaccines that are globally accessible. Using a platform conjugation technology, highly immunogenic conjugate vaccines were produced that elicit broad cross-neutralization to variants of concern (VOC), manufactured cheaply compared to mRNA vaccines. Protein-protein conjugates and Toll-Like Receptor (TLR) agonist adjuvants were shown to enhance immunogenicity and induce broad cross-protection against VOC, a characteristic lacking in early mRNA COVID-19 vaccines. Murine nAb titers from Beta-only conjugates were equivalent between Beta, Delta, Omicron BA.1, BA.2, and BA.4/BA.5, which were circulating up to three years after the antigenic strain. Additionally, Beta-Delta bivalent conjugate vaccines readily prevented disease in hamster challenge, which demonstrates a vaccine with remarkably broad cross-protection and potential to protect for extended periods despite mutations, without requiring expensive boosters or antigen adaption. This vaccine can be produced in our highly automated, large-scale manufacturing facility enabling economical production of inexpensive, effective vaccines for high-need areas.
Resumen de: US20260097007A1
0000 Provided herein are methods for the treatment, mitigation, and prevention of viral infections (e.g., coronavirus infections (e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etc.), etc.) and diseases (e.g., Coronavirus disease 2019 (COVID-19)) associated therewith by the administration of cysteamine or derivatives thereof to a subject.
Resumen de: US20260097051A1
Compositions and methods for treating or reducing symptoms of acute respiratory distress syndrome (ARDS) generally and COVID-19 infection, in particular, are provided. An exemplary method includes administering to the subject an effective amount of cannabichromene to reduce acute respiratory distress caused by ARDS generally and COVID-19 infection, in particular.
Resumen de: EP4722231A1
A biosynthesis method for a broad-spectrum antiviral polypeptide. The present invention specifically relates to a biosynthesis method for a polypeptide HCoV-EK1 capable of inhibiting human coronavirus infections in a broad-spectrum manner. The specific process comprises: construction of an Escherichia coli genetically engineered bacterium, fermentation culture of the Escherichia coli genetically engineered bacterium, and purification of recombinant polypeptide HCoV-EK1.
Resumen de: UA162619U
Method for polarization-phase interferometry of the optically anisotropic architectonics of fibrillar and parenchymal tissue specimens from deceased individuals who suffered from COVID-19, by means of polarization mapping of laser microscopic images of native histological sections of biological tissues with algorithmic reconstruction of integrated average phase maps of the polycrystalline architectonics of biological layers through the measurement of coordinate distributions of partial elements of the polarization matrix. To evaluate changes in the layer-by-layer phase maps of the optically anisotropic architectonics of fibrillar (myocardium) and parenchymal (kidney) tissue specimens from the deceased, native histological section samples of deceased individuals who suffered from COVID-19 are placed in the optical beam path of a Mach-Zehnder polarization interferometer. A series of plane-polarized (with polarization azimuths of 0°, 90°, 45°, 135°) and circularly left-hand 5 and right-hand polarized irradiating and reference laser beams are formed; for each polarization state, the irradiating beam is directed by means of a rotating mirror onto the native histological section sample of the deceased who suffered from COVID-19, the laser image of which is projected by a polarization micro-objective into the plane of photosensitive pixels of a digital camera, while a series of reference beams with polarization states of 0°, 90°, 45°, 135°, a, , are sequentially directed by
Resumen de: EP4722230A1
0001 The present invention relates to an immunogenic composition comprising a recombinant peptide and protein, wherein the recombinant peptide and protein comprise a coronavirus antigen and immunogen, for example, a chimeric antigen and immunogen of an S protein peptide or a fragment, variant or mutant sequence thereof of SARS-CoV-2 Hu-1, SARS-CoV-2 Omicron (BA.5 and/or XBB.1.5) variant, and/or other variants. The immunogenic composition comprises a secreted fusion protein, which comprises a soluble coronavirus antigen, wherein the soluble coronavirus antigen protein is linked, by means of in-frame fusion, to a C-terminal moiety of a collagen capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. The immunogenic composition can be used for generating an immune response, and can be used in a vaccine composition. Further provided are methods for producing a recombinant peptide and protein, methods for prevention, treatment and/or diagnosis, and a related kit.
Resumen de: US20260091107A1
The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus Infection, preferably a Coronavirus infection.
Resumen de: US20260091066A1
A composition containing a culture supernatant of dental pulp-derived stem cells, adipose-derived stem cells, umbilical cord-derived stem cells or immortalized stem cells thereof in which the composition contains angiotensin-converting enzyme 2 (ACE2) and is used for administration to a healthy person or a healthy animal for preventing infection of the healthy person or the healthy animal with a virus that uses ACE2 as a receptor can be used as a medicine for preventing infection with a virus that uses ACE2 as a receptor, such as COVID-19, or the like when administered to a healthy person or a healthy animal.
Resumen de: WO2026073202A1
Disclosed herein are receptor binding domain (RBD) SARS-CoV-2 immunogens, engineered nanoparticle vaccines comprising receptor binding domain (RBD) SARS-CoV-2 immunogens and methods of use thereof for SARS- CoV-2 vaccines.
Resumen de: WO2026072651A1
A method of treating a viral disease associated with targeting of PDZ domain proteins by a viral disease-inducing virus, in a subject in need of such therapy, comprising administering to the subject an inhibitor of at least one of 20s proteasome subunit β6 (Prosβ6), 20s proteasome subunit β2 (Prosβ2), and β-Transducin repeat-containing protein (βTrCP), thereby causing the death of cells that have been infected by the viral disease-inducing virus. The viral disease-inducing virus may be, for example, HPV, Adenovirus, Influenza A, HTLV-1, HIV, West Nile, Dengue, or SARS-CoV. Hie HPV may be a high-risk HPV strain such as HPV strain 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, or 68. The viral disease may be an HPV-induced cancer.
Resumen de: UA130623C2
This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of human coronavirus 2019-nCoV.
Resumen de: NZ791549A
Use of a compound represented by formula (I) or pharmaceutically acceptable salts thereof in the preparation of drugs for preventing or treating coronavirus infectious diseases. The compound represented by formula (I) is used for treating patients with novel coronavirus pneumonia, and shows obvious advantages in negative conversion ratio of viral nucleic acid test, negative conversion course, and cure and hospital discharge time.
Resumen de: US20260083762A1
The present invention relates to the use of compositions comprising sialic acid to inhibit or treat coronavirus infections, and in particular those caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).
Resumen de: US20260085367A1
A LAMP assay system for detection of a respiratory virus is disclosed. The LAMP system includes a LAMP reaction mixture having a primer kit, a strand-displacing polymerase and deoxyribonucleoside triphosphates for amplifying a target sequence. The primer kit includes at least one of a first primer set specific to SARS-CoV-2, a second primer set specific to Influenza A, and a third primer set specific to Influenza B. The first primer set includes primers having nucleotide sequences of SEQ ID NOs: 1 to 6 and SEQ ID NOs: 13 to 18. The second primer set includes primers having nucleotide sequences of SEQ ID NOs: 25 to 30. The third primer set includes primers having nucleotide sequences of SEQ ID NOs: 44 to 49.
Resumen de: US20260088185A1
Systems and methods are provided for treating blood clots associated with a replicating pathogen, such as a virus in the coronaviridae family. The systems and methods include applying an electrical impulse transcutaneously through the outer skin surface of the patient to a cervical branch of the vagus nerve of the patient. The electrical impulse is sufficient to reduce a number of antibodies associated with blood clotting to reduce a level of blood clotting in the patient. The systems and methods are particularly useful for treating post-COVID conditions or post-acute sequelae of COVID-19 that develop in “long-haul” or COVID patients.
Resumen de: US20260085087A1
A chemical compound having a triazine group and a method for production thereof are related to novel compounds and methods for production thereof in nucleotide chemistry. In particular, the present invention relates to nucleotides and oligonucleotides comprising a modified phosphate group, and to the method for production thereof. The present invention may be used in cytological studies, in DNA- or RNA-containing pathogen diagnostics, in gene therapy as well as in treating various bacterial and viral diseases, including COVID-19. The objective of the present invention is to provide compounds having a therapeutic potential as well as to develop the available method for production thereof.
Resumen de: US20260083835A1
A non-infections bacteriophage T4 nanoparticle vaccine composition includes a bacteriophage capsid and at least one antigen displayed on the surface of the capsid or packaged in its interior. The vaccine is administered intranasally and is free of an adjuvant. The antigen is selected from respiratory viruses including coronavirus and influenza.
Nº publicación: US20260085063A1 26/03/2026
Solicitante:
RUTGERS THE STATE UNIV OF NEW JERSEY [US]
Rutgers, The State University of New Jersey
Resumen de: US20260085063A1
The present disclosure relates, in part, to SARS-CoV-2 papain-like protease (PLpro) inhibitor compounds of Formula (I), pharmaceutical compositions thereof, and methods of using the same for promoting an antiviral effect in a subject and/or treating, preventing, and/or ameliorating a viral infection in a subject:
BOPI
Sede Electrónica
